BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
latest_posts
- 1
Step by step instructions to Explore Assessment Ramifications of Disc Rates - 26 Agreeable Earphones To Wear
- 3Most loved Web-based feature: Which Stage Do You Like
- 4Tire Brands for Senior Drivers: Guaranteeing Security and Solace
- 5Ads promising cosmetic surgery patients a ‘dream body’ with minimal risk get little scrutiny
- Home Security Frameworks with Shrewd Elements
- Rachael Ray is navigating grief this holiday season. She doesn't have time for 'negative energy' on the internet.
- Flights canceled at 40 U.S. airports: Follow live updates as FAA cuts to air traffic take effect amid government shutdown
- The Development of Shipping: Controlling Towards a More Associated Future
- Remarkable Spots for Hot Air Swelling All over The Planet
- New Gaza militia declares war on Hamas: 'Your dirty shoes are more honorable'
- Figure out How to Really focus on Your Dental Inserts for Durable Outcomes
- First Greenland, now Iceland? Annexation joke by Trump ally gets frosty response in the Arctic nation.
- Roche breast cancer pill cuts risk of disease recurrence by 30% in trial
